Bioheaven gets USFDA go ahead to begin phase 2 trial of intranasal vazegepant to treat lung inflammation after COVID-19 infection Medical Dialogues Bureau12 April 2020 8:00 AMVazegepant is currently advancing to Phase 3 development for the acute treatment of migraines in adults under the Division of Neurology, having...
Biohaven Nurtec™ ODT (rimegepant) launch in US market for migraine in adults Medical Dialogues Bureau16 March 2020 3:30 AMTreatment with NURTEC ODT is simple – a single dose of 75 mg provides fast pain relief, returns patients to normal function within one hour, and...
Biohaven Receives Fda Approval for acute migraine drug Medical Dialogues Bureau1 March 2020 7:00 AMA single quick-dissolving tablet of NURTEC ODT can provide fast pain relief and return patients to normal function within one hour, and deliver...
FDA approves Lundbeck's intravenous migraine prevention drug Vyepti, to launch in April 2020 Medical Dialogues Bureau23 Feb 2020 6:00 AMDeerfield: Lundbeck announced that VYEPTI™ (eptinezumab-jjmr) has been approved by the U.S. Food and Drug Administration (FDA) for the preventive...
Dr Reddys to sell Tosymra, Zembrace to Upsher-Smith Labs for Rs 765 crore approx Farhat Nasim15 Jun 2019 4:30 AMDr Reddy's (Dr Reddys) Labs said Tosymra and Zembrace were designed and developed with the goal of addressing unmet needs of large but discrete...
Eli Lilly to present new data on Emgality, Lasmiditan at AAN annual meeting Farhat Nasim5 May 2019 4:30 AMEmgality is also currently under Priority Review by the FDA as an investigational drug for the preventive treatment of episodic cluster headache in...
Novartis Aimovig not cost effective: UK price watchdog Medical Dialogues Bureau11 Jan 2019 3:30 AMNovartis, whose U.K. price for Aimovig is about 5,000 pounds ($6,374) annually but which was offering discounts, is counting on the medicine to be a...
Zydus gets USFDA nod for seizure, migraine drug Ruby Khatun Khatun28 Nov 2017 8:23 AMNew Delhi: Drug firm Zydus Cadila said it has received final approval from the US health regulator to market Topiramate extended-release capsules,...
